The Top 60: EvoLogue

Share this article:
CommonHealth's freshly established consumer group, EvoLogue, was founded in September 2007, and made strides during its first year. “We rebuilt the consumer offerings from CommonHealth to reflect and redefine communication between patients and physicians,” says Meg Walsh, managing partner, president EvoLogue and e-Business. 

Key hires and personnel include Shelagh Brooke, chief strategic officer; Mark Robinson, chief operating officer; Mark Kosak and Steve Pashkoff, co-chief creative officers; and Ann Friedman Ryan, managing director, CRM, eCRM, interactive. 

“We've done a good job getting back into bigger pharmaceutical clients, like Pfizer, Novartis and Merck,” says Walsh. “We spent a lot of time innovating what is called ‘consumer communications.' Our Motivational Efficacy program is a new look at behavior modification. Patient/consumer communications needs to change to increase compliance and consistency. We need to help patients understand the context of their disease in their life, and that occurs through dialogue and interactions,” she says.
“EvoLogue,” a portmanteau word combining “evolution” and “dialogue,” is a full-service agency heavy on strategy. “Our strategy includes physician panels, patient story tellers and interactive tools. We tag everything, linguistically analyze it, note pattern recognition, and act on that information,” explains Walsh. 

In several areas, EvoLogue is breaking new ground. “[Reckitt Benckiser Inc.'s] Suboxone was the first pharmaceutical product on MySpace,” says Walsh. “Whether it's wireless communications, social networks or web development, we're integrating the technology into all of our work. We see it as a way to give patients a tool and opportunity for high engagement—not just information posting. Most of our strategies have a call to action on the web,” she says.

In 2007, the agency won the AOR account on AstraZeneca's Symbicort that includes multicultural duties. Walsh says multicultural work is handled exactly the same way as a traditional campaign. “The reason we work on multicultural, whether it's customer relationship management (CRM) or an ad campaign, is that it's no longer a separate effort.” 

That doesn't necessarily mean the creative is identical. “Does [the work] have cultural nuance? You bet,” says Walsh. Other new wins in 2007 include Novartis' influenza vaccines and McNeil Nutritionals' Splenda.

Regarding CRM, Walsh believes that new needs have to be addressed. 

“We're moving into milestone marketing,” she says. “People don't relate to scare tactics, like people with missing limbs in smoking campaigns. If you look at the way Alcoholics Anonymous and Weight Watchers have approached this, they're good examples of promoting a lifestyle commitment, not a punishment, and that's what milestone marketing is all about. We have to set expectations properly with medications. If a patient is going to experience a side effect, they should know that beforehand.” 

EvoLogue has transitioned from a majority of professional accounts to huge DTC clients. “In the next five years, we'll continue to promote interaction, follow-up dialogue among patients, with an emphasis on compliance and consistency. We're looking for clients who understand that,” says Walsh. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.